Toxicology News and Research

Latest Toxicology News and Research

NWO awards 31 grants in Investment Subsidy NWO Medium programme

The Netherlands Organisation for Scientific Research (NWO) has awarded 31 grants in the Investment Subsidy NWO Medium programme for the acquisition of equipment, the setting up of data collections and the production of software and bibliographies. The total investment amounts to 10 million euro.

30 Apr 2010

Experts discuss recent advancements in personalized medicine for treating childhood disorders

Many of the world's leading experts in pediatric pharmacogenomics and personalized medicine are gathering today at a first-of-its-kind conference in Kansas City to change the way childhood diseases and illnesses are treated.

29 Apr 2010

Fluorescent inhibitors hold promise for early-stage tumor detection

A series of novel imaging agents could light up tumors as they begin to form - before they turn deadly - and signal their transition to aggressive cancers.

29 Apr 2010

A new approach for treating neurological and degenerative disorders

In studies on cancer, heart disease, neurological disorders and other degenerative conditions, some scientists are moving away from the "nature versus nurture" debate, and are finding you're not a creature of either genetics or environment, but both - with enormous implications for a new approach to health.

29 Apr 2010

Lycera to advance discovery, development efforts with second tranche of $11 million Series A financing

Lycera Corporation, a biopharmaceutical company pioneering an innovative approach to developing novel oral medicines to treat autoimmune diseases, today announced that the company has made important progress, triggering a second tranche of $11 million in its Series A financing. Proceeds from the second tranche will be used to continue to advance Lycera's discovery and development efforts and further support the growth of the company.

29 Apr 2010

Dietary MSC can help reset cell's biological clock to prevent development of breast cancer: Study

Usually when all else fails with a technical device, a "reset" button can be pressed, preventing a glitch from going any further. What if that could be done with threats to a person's health? Investigators from The Cancer Institute of New Jersey and the Environmental & Occupational Health Sciences Institute which is jointly administered by UMDNJ-Robert Wood Johnson Medical School and Rutgers, The State University of New Jersey, have discovered that a form of a dietary trace element known as selenium can help reset a cell's "biological clock" when it is disrupted by a chemical cancer-causing agent (carcinogen).

28 Apr 2010

Charles River Laboratories International, WuXi PharmaTech sign definitive agreement to combine

Charles River Laboratories International, Inc., a leading global provider of research models and associated services and of preclinical drug development services, and WuXi PharmaTech, a leading drug research and development outsourcing company with expertise in discovery chemistry and with operations in China and the United States, today announced that they have signed a definitive agreement under which Charles River and WuXi will combine in a cash and stock transaction valued at approximately $1.6 billion.

26 Apr 2010

isrp awarded $16M grant to study health effects of environmental pollutants

The National Institute of Environmental Health Sciences has awarded the University of Iowa Superfund Research Program (isrp) a five-year, $16 million grant to study the health effects of environmental pollutants, especially polychlorinated biphenyls (PCBs) found in water, former industrial sites and the atmosphere.

23 Apr 2010

Report highlights 11 key categories of diseases, health consequences that occur due to climate change

A report released today by a federal working group highlights 11 key categories of diseases and other health consequences that are occurring or will occur due to climate change. The report, A Human Health Perspective on Climate Change, provides a starting point for coordination of federal research to better understand climate's impact on human health.

22 Apr 2010

First-of-its-kind conference on personalized medicine for pediatric patients

The world's leading experts in pediatric pharmacogenomics and personalized medicine are gathering at a first-of-its-kind conference in Kansas City to change the way childhood diseases and illnesses are treated through personalized medicine.

22 Apr 2010

miRNAs may generate new insights on cancer and possible future treatments

Scientists are methodically unlocking the biological processes that lead to cancer, and recent discoveries with microRNAs (miRNAs) are revolutionizing their understanding and leading to clinical trials of potentially effective treatments.

21 Apr 2010

Caliper Life Sciences introduces Quantum FX stand-alone microCT system for preclinical imaging

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery, life sciences research and molecular diagnostics, today announced the Quantum FX, a stand-alone microCT system for preclinical imaging. Introduced at the American Association for Cancer Research Annual Meeting 2010, the Quantum FX is a low dose, microCT system that provides researchers with a 3-dimensional anatomical view of disease activity, tumor development and therapeutic response over multiple time points during the course of a study.

19 Apr 2010

Phase II study: Hepatitis C patients receiving ANA598 bid plus SOC attain undetectable levels of virus

Anadys Pharmaceuticals, Inc. announced today that 72% of hepatitis C patients receiving ANA598 400 mg twice daily (bid) plus standard of care achieved undetectable levels of virus at week eight in an ongoing Phase II study, compared to 38% of patients receiving placebo plus SOC.

19 Apr 2010

New p53 knockout rat model improves timelines for carcinogenicity screening

Sigma Life Science, the innovative biological products and services brand of Sigma-Aldrich, today introduced the world's first p53 'knockout' rat model, an important development that is expected to, due to the rat's closer physiological and metabolic similarity to humans, significantly improve timelines for carcinogenicity screening and reduce time to market for therapeutics.

19 Apr 2010

VisEn Medical expands FMT imaging platform

VisEn Medical Inc., a leader in fluorescence imaging solutions from research through medicine, announced today that it has expanded its leading FMT imaging platform with an FMT™ Multi-Species Imaging Module, to extend FMT imaging and related applications into larger preclinical animal models. VisEn also announced that it will be presenting new study results from its recently-launched Cat B 750 FAST™ and Annexin-Vivo™ fluorescence imaging agents at the AACR 101st Annual Meeting.

16 Apr 2010

TruthAboutGardasil.org: Governments need to suspend HPV vaccinations/programs

The global outrage at reports of injustices inflicted on the children of India from unethical trials and experimentation of HPV vaccines in socially disadvantaged groups extends to women and children worldwide subjected to similar violations.

16 Apr 2010

InterMune reports Phase 1b MAD study results of RTV-boosted danoprevir in HCV patients at 45th EASL

InterMune, Inc. today announced results of all three cohorts from a 15-day Phase 1b multiple-ascending-dose (MAD) study of low doses of danoprevir (also known as RG7227 and ITMN-191) boosted by low-dose ritonavir (RTV) in patients chronically infected with hepatitis C virus (HCV) genotype-1.

16 Apr 2010

Study: Circadian’s anti-cancer therapy reduces tumour growth in animal models

Circadian Technologies Limited today released data demonstrating that its lead anti-cancer therapeutic, VGX-100, significantly inhibits tumour growth in a variety of different animal models (tumour xenografts) of human cancer.

16 Apr 2010

Cequent Pharmaceuticals commences toxicology study of CEQ508 tkRNAi-based therapeutic candidate

Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has initiated a long-term (26-week) toxicology study of CEQ508 – the company's lead drug candidate based on its proprietary tkRNAi technology. This study is designed to enable a Phase II clinical trial slated for 2011. CEQ508 targets beta-catenin, a key oncogene implicated in the formation of colonic polyps and in the progression of polyps to colorectal cancer.

16 Apr 2010

UALR researcher receives federal grant to track estrogen-mimicking compounds in consumer products

Dr. Jerry Darsey, professor of chemistry in UALR's College of Science and Mathematics, has received $77,000 from a federal Food and Drug Administration grant to develop methods to track estrogen mimicking compounds in various products and assess how use of the products affect women.

16 Apr 2010

Toxicology News and Research

Latest Toxicology News and Research

NWO awards 31 grants in Investment Subsidy NWO Medium programme

Experts discuss recent advancements in personalized medicine for treating childhood disorders

Fluorescent inhibitors hold promise for early-stage tumor detection

A new approach for treating neurological and degenerative disorders

Lycera to advance discovery, development efforts with second tranche of $11 million Series A financing

Dietary MSC can help reset cell's biological clock to prevent development of breast cancer: Study

Charles River Laboratories International, WuXi PharmaTech sign definitive agreement to combine

isrp awarded $16M grant to study health effects of environmental pollutants

Report highlights 11 key categories of diseases, health consequences that occur due to climate change

First-of-its-kind conference on personalized medicine for pediatric patients

miRNAs may generate new insights on cancer and possible future treatments

Caliper Life Sciences introduces Quantum FX stand-alone microCT system for preclinical imaging

Phase II study: Hepatitis C patients receiving ANA598 bid plus SOC attain undetectable levels of virus

New p53 knockout rat model improves timelines for carcinogenicity screening

VisEn Medical expands FMT imaging platform

TruthAboutGardasil.org: Governments need to suspend HPV vaccinations/programs

InterMune reports Phase 1b MAD study results of RTV-boosted danoprevir in HCV patients at 45th EASL

Study: Circadian’s anti-cancer therapy reduces tumour growth in animal models

Cequent Pharmaceuticals commences toxicology study of CEQ508 tkRNAi-based therapeutic candidate

UALR researcher receives federal grant to track estrogen-mimicking compounds in consumer products

Forensics and toxicology - Industry Focus eBook eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Toxicology News and Research

Latest Toxicology News and Research

Forensics and toxicology - Industry Focus eBook eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in